Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.

MLA

Baldini, Capucine, et al. “Safety, Recommended Dose, Efficacy and Immune Correlates for Nintedanib in Combination with Pembrolizumab in Patients with Advanced Cancers.” Journal of Experimental & Clinical Cancer Research (17569966), vol. 41, no. 1, July 2022, pp. 1–14. EBSCOhost, https://doi.org/10.1186/s13046-022-02423-0.

APA

Baldini, C., Danlos, F.-X., Varga, A., Texier, M., Halse, H., Mouraud, S., Cassard, L., Champiat, S., Signolle, N., Vuagnat, P., Martin-Romano, P., Michot, J.-M., Bahleda, R., Gazzah, A., Boselli, L., Bredel, D., Grivel, J., Mohamed-Djalim, C., Escriou, G., & Grynszpan, L. (2022). Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. Journal of Experimental & Clinical Cancer Research (17569966), 41(1), 1–14. https://doi.org/10.1186/s13046-022-02423-0

Chicago

Baldini, Capucine, Francois-Xavier Danlos, Andreea Varga, Matthieu Texier, Heloise Halse, Severine Mouraud, Lydie Cassard, et al. 2022. “Safety, Recommended Dose, Efficacy and Immune Correlates for Nintedanib in Combination with Pembrolizumab in Patients with Advanced Cancers.” Journal of Experimental & Clinical Cancer Research (17569966) 41 (1): 1–14. doi:10.1186/s13046-022-02423-0.